These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26875581)

  • 21. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.
    Kim YJ; Kim SI; Hong KW; Kim YR; Park YJ; Kang MW
    J Korean Med Sci; 2012 May; 27(5):471-5. PubMed ID: 22563209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Investigation on Nosocomial Infection of Acinetobacter baumannii and the Clinical Analysis of Sequential Therapy of Cefoperazone/Sulbactam Sodium for Intracranial Infection.
    Xiong Z; Zeng D; Shen S; Han Z
    Comput Math Methods Med; 2022; 2022():4525892. PubMed ID: 36017154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant
    Niu T; Xiao T; Guo L; Yu W; Chen Y; Zheng B; Huang C; Yu X; Xiao Y
    Infect Drug Resist; 2018; 11():2021-2030. PubMed ID: 30464544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk and Prognostic Factors for Multidrug-Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China.
    Liu Q; Li W; Du X; Li W; Zhong T; Tang Y; Feng Y; Tao C; Xie Y
    PLoS One; 2015; 10(6):e0130701. PubMed ID: 26083415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
    Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
    Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling and forecasting Acinetobacter baumannii resistance to set appropriate use of cefoperazone-sulbactam: Results from trend analysis of antimicrobial consumption and development of resistance in a tertiary care hospital.
    Xie J; Wang Y; Zheng X; Yang Q; Wang T; Zou Y; Xing J; Dong Y
    Am J Infect Control; 2015 Aug; 43(8):861-4. PubMed ID: 26033693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia.
    Kang FY; How CK; Wang YC; Cheng A; Yang YS; Kuo SC; Liu CP; Liu YM; Chen TL; Lee YT
    Antimicrob Resist Infect Control; 2020 Sep; 9(1):160. PubMed ID: 32993810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors.
    Chiang MC; Kuo SC; Chen SJ; Yang SP; Lee YT; Chen TL; Fung CP
    Infection; 2012 Feb; 40(1):19-26. PubMed ID: 21887526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
    Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
    J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
    Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
    Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities?
    Lee YT; Kuo SC; Yang SP; Lin YT; Chiang DH; Tseng FC; Chen TL; Fung CP
    Clin Microbiol Infect; 2013 Jul; 19(7):640-5. PubMed ID: 22967204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes.
    Lee YC; Huang YT; Tan CK; Kuo YW; Liao CH; Lee PI; Hsueh PR
    J Antimicrob Chemother; 2011 Aug; 66(8):1839-46. PubMed ID: 21653602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections.
    Li Y; Xie J; Chen L; Meng T; Liu L; Hao R; Dong H; Wang X; Dong Y
    Pak J Pharm Sci; 2020 Jan; 33(1):161-168. PubMed ID: 32122844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for mortality in patients with Acinetobacter baumannii bloodstream infection with genotypic species identification.
    Chiang DH; Wang CC; Kuo HY; Chen HP; Chen TL; Wang FD; Cho WL; Liu CY
    J Microbiol Immunol Infect; 2008 Oct; 41(5):397-402. PubMed ID: 19122921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.
    Özvatan T; Akalın H; Sınırtaş M; Ocakoğlu G; Yılmaz E; Heper Y; Kelebek N; İşçimen R; Kahveci F
    Respirology; 2016 Feb; 21(2):363-9. PubMed ID: 26635315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Effective Antimicrobial Regimens and Mortality-Related Risk Factors for Bloodstream Infections Caused by Carbapenem-Resistant
    Gu S; Xiong J; Peng S; Hu L; Zhu H; Xiao Y; Luo H; Hang Y; Chen Y; Fang X; Cao X; Fang Y; Li F; Zhu J; Zhong Q
    Infect Drug Resist; 2023; 16():2589-2600. PubMed ID: 37152405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
    Lv Q; Deng Y; Zhu X; Ruan J; Chen L
    J Coll Physicians Surg Pak; 2020 Mar; 30(3):332-334. PubMed ID: 32169149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
    Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study.
    Russo A; Bassetti M; Ceccarelli G; Carannante N; Losito AR; Bartoletti M; Corcione S; Granata G; Santoro A; Giacobbe DR; Peghin M; Vena A; Amadori F; Segala FV; Giannella M; Di Caprio G; Menichetti F; Del Bono V; Mussini C; Petrosillo N; De Rosa FG; Viale P; Tumbarello M; Tascini C; Viscoli C; Venditti M;
    J Infect; 2019 Aug; 79(2):130-138. PubMed ID: 31145911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.